Published in final edited form as:

Adv Mater. 2018 July ; 30(27): e1800242. doi:10.1002/adma.201800242.

Microfluidics-Enabled Multi-Material Maskless Stereolithographic Bioprinting

Amir K. Miri Dr.,

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.

Daniel Nieto[#] [Prof.],

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139. Microoptics and GRIN Optics Group, Applied Physics Department, Faculty of Physics, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain

Luis Iglesias[#],

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.

Hossein Goodarzi Hosseinabadi[#],

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139. Polymeric Materials Research Group, Department of Materials Science and Engineering, Sharif University of Technology, Tehran, P.O. Box 11155-9466, Iran

Sushila Maharjan Dr.[#],

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.

Guillermo Ulises Ruiz-Esparza Dr.,

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.

Parastoo Khoshakhlagh,

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.

Amir Manbachi Dr.,

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.

Mehmet Remzi Dokmeci Dr.,

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.

Shaochen Chen,

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139. Department of NanoEngineering, University of California, San Diego, La Jolla, CA 92093, USA, Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA, Materials Science and Engineering Program, University of California, San Diego, La Jolla, CA 92093, USA

Su-Ryon Shin Dr.,

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.

Yu Shrike Zhang* Dr., and

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.

Ali Khademhosseini* [Prof.]

Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139. Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA 90095, USA, Department of Radiology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA, Department of Bioengineering, Department of Chemical and Biomolecular Engineering, Henry Samueli School of Engineering and Applied Sciences, University of California-Los Angeles, Los Angeles, CA 90095, USA, California NanoSystems Institute (CNSI), University of California-Los Angeles, Los Angeles, CA 90095, USA, Department of Bioindustrial Technologies, Konkuk University, Seoul, Republic of Korea

# These authors contributed equally to this work.

Abstract

This communication presents a stereolithography-based bioprinting platform for multi-material fabrication of heterogeneous hydrogel constructs. Dynamic patterning by a digital micro-mirror device (DMD), synchronized by a moving stage and a microfluidic device containing four on/off pneumatic valves, is used to create 3D constructs. The novel microfluidic device is capable of fast switching between different (cell-loaded) hydrogel bioinks, to achieve layer-by-layer multi-material bioprinting. Compared to conventional stereolithography-based bioprinters, our system

provides the unique advantage of multi-material fabrication capability at high spatial resolution. To demonstrate the multi-material capacity of our system, a variety of hydrogel constructs are generated, including poly(ethylene glycol) diacrylate (PEGDA) and gelatin methacryloyl (GelMA). The biocompatibility of our system is validated by introducing cell-laden GelMA into the microfluidic device and fabricating cellularized constructs. A pattern of PEGDA frame and three different concentrations of GelMA, loaded with vascular endothelial growth factor, is further assessed for its neovascularization potential in a rat model. The proposed system provides a robust platform for bioprinting of high-fidelity microstructures on demand for applications in tissue engineering, regenerative medicine, and biosensing, which are otherwise not readily achievable at high speed with conventional stereolithographic biofabrication platforms.

Keywords

Digital light prototyping; digital micro-mirror device; bioprinting; microfluidics; multi-material

In nature, multiscale structures with hierarchical microscale features are consequences of conditions reached during material optimization when organizing underlying components with regards to external environments.^[1] Such material optimization can be found in the bifurcation of human organs such as liver,^[2] retina,^[3] vein,^[1] and arteries.^[4] To fabricate biomimetic structures resembling their natural counterparts, existing additive manufacturing methods such as freeze-drying^[5] and salt-leaching^[6] lack flexibility to tune the design regionally. Photolithography^[7] and laser sintering^[8] have been introduced to fabricate geometries at high precisions. Laser sintering techniques suffer from practical limitations in terms of construct resolution, the manufacturing speed, and the used material composition. Regarding the success of photolithography, common light-assisted three-dimensional (3D) printing systems including continuous digital light processing (DLP),^[9] DLP-based 3D printing,^[10] mask-projection micro-stereolithography^[11] or dynamic mask stereolithography^[12] have been used so far. Most of these systems represent top-down projection approaches, while bottom-up projection approaches can provide quicker build-up time, higher resolution, and material conservation.^[13]

The digital micro-mirror device (DMD)-based projection printing has emerged as a high-throughput DLP technique offering great biocompatibility for cell seeding and encapsulation.^[14] DMD is a micro-electro-mechanical system that enables a user to control over one million small mirrors to turn-on or turn-off on the order of kHz. An ultraviolet (UV) lamp projects high-intensity light on the DMD panel, in which patterns the image of each layer of the computer-aided-design (CAD) model, and projects into the bottom side of the container. Following this UV exposure, the photosensitive polymer or hydrogel crosslinks and attaches to the previous layer. DMD-based printing offers high-quality surface finishing and a variety of material options.^[11] Conventional DLP-based techniques are slow and their use in fabricating cell-laden constructs with clinically relevant dimensions is thus very challenging.^[7] Following benchmark multi-material stereolithography designs by adapting commercial printers to function with several ink reservoirs^[15], Bashir's group designed a DMD-based bioprinting apparatus to generate multi-component biohybrid myocardium-based actuators, by manually changing the bath solutions.^[16] We have

previously developed a high-precision DMD-based bioprinter for multi-purpose uses, and fabricated a 3D hydrogel-based tri-culture model using pluripotent stem cell (hiPSC)-derived hepatic progenitor cells, human umbilical vein endothelial cells, and adipose-derived stem cells in a microscale hexagonal architecture.^[2] The potential of DMD-based bioprinters in fabrication of microfluidic platforms used in medical diagnostics was also demonstrated.^[17] Despite these significant advantages, several key challenges for fabricating biomimetic tissue constructs still remain, including the inability for continuous fabrication of cell-laden constructs with clinically relevant dimensions and the inability to bioprint multicomponent complex constructs with high precision. A core challenge in the use of multiple materials is how to manage material contamination between changing different materials used in the printing process. Among various photopolymers, gelatin methacryloyl (GelMA)^[2] and poly(ethylene glycol) diacrylate (PEGDA)^[18] have shown great biocompatibility for cell encapsulation.

Here we show that the integration of a simple microfluidic platform can advance the DMD-based bioprinter for proper fabrication of inhomogeneous GelMA and PEGDA constructs at high fidelity. Models could be conveniently converted into segmented images or bit data and then imported into the DMD-based bioprinter interface to fabricate desired geometries and shapes. The integration of multiple independent bioink injections further offered easy feeding of different materials with fast switching. Computational fluid dynamics was used to assess the performance of the microfluidic system for multi-material patterning. Various patterns were fabricated through this platform to validate its multi-material bioprinting capability. We further evaluated the flexibility and biocompatibility of the platform to generate biomimetic heterogeneous tissue constructs by using bioinks loaded with multiple cell types, introduced from the microfluidic chips into the DMD bioprinter.

The DMD-based bioprinter uses UV light (up to 500 mW/cm²) to polymerize a liquid prepolymer towards a solid structure (Figure 1). The DMD panel that is an array of reflective-coated micro-mirrors creates light patterns at high definition (i.e. 1050 × 920) and speed (10 kHz rate of switching). The digital state of each micro-mirror can be controlled as being either 0 (dark) or 1 (light-reflecting for photo-polymerization) while the bioink is introduced to the focal plane of the projected image, leading to its crosslinking in a layer-by-layer fashion. We calibrated the image size by printing a single image featuring a grid pattern, and then measuring the grid by a light microscope. The lateral resolution is theoretically limited by the physical size of DMD mirrors, which is 7.6 μm for the selected model; however, experimental printing resolution (i.e., smallest feature size) was determined at the order of 10 μm (Figure S1). Simple patterns were used to show printing capabilities of our DMD-based bioprinter over a range of UV exposure parameters and photoinitiator concentrations. The photoinitiator concentration affected the time required to fully crosslink the hydrogel from seconds to minutes. The practical resolution of our bioprinter was further shown by printing parallel lines, in which it generated a line thickness down to ~25 μm (Figure S1f).

Different from existing DMD bioprinters, we developed a unique microfluidic device to turn our system into a multi-material stereolithographic bioprinting platform. Figure 2a illustrates the design of the microfluidic device consisting of one polydimethylsiloxane (PDMS) chamber held between two poly(methyl methacrylate) (PMMA) sheets and four inlets,

which allowed for sequential injection of different bioinks (Figure 2b). The three branches in the middle region were introduced to widen the directionality of the washing flow and reduce flow forces imposed on the printed construct (as seen by experimental observations in Figure 2). Bioink flow filled the chip in a few seconds, before subjecting to UV crosslinking. Phosphate-buffered saline (PBS) then washed away the first bioink within the same time frame, and this was repeated for the second and following bioinks. In addition, we assessed chip performance by tracking dye particles in dye-filled bioink flows within the microfluidic device and washing by the subsequent bioink (in a different color), or PBS. Figure 2c shows the simulation of our numerical model for flow patterns around the star shape, indicating a close similarity (correlation coefficient > 0.70) in the flow patterns observed around the star shape (Figure S2a; left image *versus* right image). Figures 2d-f provide a direct visual impression on how the bioinks were washed when different shapes were printed inside the chamber. Despite the presence of branching and potential turbulence at edges, we were able to observe reasonable laminar flow in the printing region with a high-speed digital camera. As expected for micro-channels, the viscous bioink was reaching to the printing region in a laminar regime ($Re \sim 10\text{--}100$), which allowed smooth transition between sequential bioink injections. However, the shape of printed construct restricted the velocity and duration of bioink feeding. The bioink could be easily washed by the subsequent flow in the case of straight lines (Figure 2e), in the absence of any dead zone or low-speed streamlines in the flow (*e.g.*, washing time ~ 5 s at an inlet velocity of 1 cm s^{-1}). In contrast, flow patterns in the case of star shape showed low-speed streamlines inside the cavities that hampered the washing process, thus requiring bioink flow at higher speed or longer time (*e.g.*, washing time ~ 20 s at an inlet velocity of 1 cm s^{-1}). When there was no object present in the chamber the flow pattern was smooth (Figure 2f; *e.g.*, washing time ~ 2 s at an inlet velocity of 1 cm s^{-1}). Moreover, we investigated how the inlet pressure, regulated by nitrogen tank, and the bioink viscosity can control maximum stress applied on the printed gel with a star shape (selected as a standard here). As summarized in Figure S2b and c, both stress and fluid velocity values are linearly correlated by inlet pressure or inlet velocity. This may allow the prevention of gel displacement by high shear stresses.

We further built an elastomeric membrane made of PDMS into our microfluidic chip, which undergoes vertical deformation during the bioprinting process to allow for the construction of 3D objects in conjunction with programmed injection of bioinks (Figure 3a and b). Starting from the first layer of crosslinking, the microfluidic chip moves up and this movement yields reduced deformation on the membrane, until its resting position (*i.e.*, for a 5-mm-high printed construct). The resilience of the membrane was studied through numerical simulation and customized mechanical testing, as summarized in Figures 3c and S3. The hyperelastic Neo-Hookean model^[19] was used to simulate the deformation field and stress distribution of the PDMS membrane for the imposed boundary conditions (Figure S3). The maximum deformation was under 50% strain when the chip was set at the initial position and it occurred at the contact region between the membrane and the rigid shell for the range of membrane thickness (from $200\text{ }\mu\text{m}$ to $500\text{ }\mu\text{m}$). The central regions had uniform strains lower than 50%, thus the deformation field is still within the elastic (*i.e.*, reversible) range of PDMS.^[20] Uniaxial tester was then employed to obtain load-displacement history of the membrane under vertical movements of the rigid shell (Figure S3), where load-

displacement curves showed hysteresis response depicting the role of friction forces on the membrane function. The membrane was programmed to load-unload when the chip was filled for printing each layer and subsequent washing, as depicted in Figure 3d; however, it was found that the presence of friction forces that yielded residual strain to a certain degree limited the number of cycles for membrane deformation, requiring future optimization for printing a very high number of layers. In the current work, we manually tightened the membrane after each construct with a relatively small thickness was printed and removed from the microfluidic chip. To the end, for printing large numbers of layers in a single construct such residual strain may become an issue requiring further optimizations. It should be noted that, the integration of such an elastomeric membrane is a unique feature in our multi-material DMD platform as it functions to seal the microfluidic chamber during the exchange of the different bioinks while providing the ability of 3D bioprinting through layer-by-layer photocrosslinking. In comparison, in a conventional DMD or DLP setup the open-chamber design would not allow for efficient injection or washing of the bioinks, therefore prohibitive of multi-material stereolithographic bioprinting.

We next demonstrated the capability of our bioprinter in generating two-dimensional (2D) and 3D constructs. Simple shapes with different materials were bioprinted using PEGDA (50% v/v) and GelMA (7% w/v) solutions, containing 2, 3, and 4 colored bioinks (Figure 3e–v). Constructs could also be fabricated in different shapes, such as eccentric circles, parallel and oblique stripes, and pyramids of different base-shapes (see also Figures S1 and S4). The planar printing resolution demonstrated the capacity of our bioprinting platform, while 3D bioprinting resolution was hampered by UV light scattering. It is noted that, while different bioinks were sequentially injected into the microfluidic chip, there was no obvious sign of mixing, indicating successful washing of bioinks prior to crosslinking, indicating the good performance of the elastomeric membrane in the microfluidic chip.

We further designed and bioprinted a set of sophisticated structures resembling biological tissues such as tumor angiogenesis, muscle strips, and musculoskeletal junctions (Figure 4a, b, and c). GelMA was used as a bioink due to its intrinsic cell adhesion moieties that promote cell spreading and functionality.^[21] Each organ-like structure had 2–4 different bioinks as each bioink was individually patterned in a rapid fashion, with smooth transitions among different bioinks. This transition that requires washing of bioink residuals in the bioprinting process can hamper cell viability as highlighted by a comparison of two different cases: single-component and two-component reticular constructs in Figure S5.

The bioprinted structures possessed explicitly separated borders among different cell-laden bioinks, confirming the role of washing (Figure 4). The printing resolution was determined to be approximately 20–30 μm , slightly reduced in comparison with non-cellular patterns due to scattering of photons from cellular components.^[22] Nevertheless, such a resolution is still compatible with our previous reports,^[2] suggesting that the addition of the microfluidic chip in the current system to introduce multiple bioinks did not exert noticeable effects on the DMD stereolithographic bioprinting process.

One of the current challenges in cancer biology is to understand the complex, multi-cellular cancer microenvironment.^[23] *In vitro* tumor cultures currently used in cancer research often

result in different cell-matrix associations that in turn affect their functions;^[24] to this end, bioprinting could become a promising strategy to engineering biomimetic cancer models due to its versatility in depositing cells and matrices in precisely defined manners.^[25] Specifically, we printed a pattern mimicking angiogenesis in a matrix of GelMA laden with scattered breast cancer cells (MCF7), followed by introduction of human umbilical vascular endothelial cells (HUVECs) within the vascular channels, as shown in Figure 4a. Such a model, although primitive, could potentially allow studying the tumor progression and angiogenesis.

Models of the musculoskeletal systems were also fabricated using our multi-material DMD-based bioprinter. Muscle bundle-like constructs were printed using two bioinks, loaded with NIH/3T3 fibroblasts and C2C12 skeletal muscle cells. The fluorescence micrograph clearly revealed the capability of the system to print the spatially distributed cell-laden bioinks (Figure 4b*ii* and *iii*), laying down the basis for future fabrication of functional muscular tissues containing hierarchical assembly of multiple cell types. The cell viability, determined immediately and at 1 and 7 days post-bioprinting, indicated that all cell types maintained satisfactory proliferation and metabolic activity (Figure 4b*iii*). In addition, we printed a construct mimicking the musculoskeletal interface integrating three different cell types, mesenchymal stem cells (MSCs), fibroblasts, and osteoblasts (Figure 4c). Again, the printed patterns were well-defined showing relatively strong similarity with the model (Figure 4c*iii* and *iv versus ii*).

The multi-material capacity of our bioprinting platform was further assessed *in vivo* in a rat subcutaneous implantation model, similar to published protocols.^[26] We designed a four-material construct made of PEGDA (35% v/v) as the framing structure and three GelMA strips with mass concentrations of 5, 10, and 15% w/v, respectively, as presented in Figure 5a*i*. Construct with vascular endothelial growth factor (VEGF) loaded in the GelMA strips was used as a positive control to stimulate angiogenesis (Figure 5a*ii* and *iii*), where blank GelMA hydrogels served as the negative control. The implants were harvested at Days 10 and 30 for histological examination and their gross appearances were first assessed (Figure 5a*iv*). It has been previously reported that VEGF induces migration of multiple endothelial cell lines, such as capillary endothelium.^[26, 27] As depicted in Figure 5b, the presence of VEGF in the bioprinted multi-material constructs did lead to the formation of more blood vessels in the implants when compared to those without VEGF. The expressions of CD31 by the invaded cells were higher in the VEGF implants at Day 10 compared to Day 30 (Figure 5c). These results showed that immobilized VEGF promoted the formation of the blood vessel network in the bioactive GelMA hydrogels, while the inert PEGDA served as the frame in the bioprinted multi-material structure.

In addition, VEGF seemed to have induced more pronounced inward growth of the connective tissues along the peripheries of the implants (Figure 5b). Our hematoxylin and eosin (H&E)-staining results further demonstrated the inflammatory responses of the host to the implants and recruitment of inflammatory cells, particularly at the interfaces of connective tissues and implants (Figure 5d).^[28] The differences in CD31 expression and connective-tissue formation were less distinctive between the 5% GelMA and the 10% GelMA compared to those in the 15% GelMA (Figure 5c-d). This may indicate that the

higher concentration of GelMA (15%) prevented the invasion of cells into the implant possibly due to the denser polymer network and reduced rate of biodegradation. The *in vivo* study suggested our ability to fabricate heterogeneous constructs using the novel multi-material stereolithographic bioprinting strategy to regulate desired biological functions such as angiogenesis.

In summary, we have demonstrated an innovative strategy by integrating a microfluidic device into the design of the DMD-based bioprinter to achieve, for the first time, automated, multi-material stereolithographic bioprinting. In a typical process, our DMD-based bioprinting platform requires only a few seconds to preform washing (if switching is required); for example, we printed non-uniform constructs, composed of 2–3 bioinks, in less than 20 s, while an industrial DMD-based printer would probably consume an additional time of 100 s simply devoted to manual bioink injections and switching.^[16, 29] Other manually operated laboratory-scale multi-material DMD-based printers would take similar time to replace the bioinks.^[2] Therefore, our bioprinter could achieve a speed faster than those of the existing stereolithography and/or DMD-based platforms. Such a speed may be further improved, through adopting a technique similar to that used in the continuous stop-flow lithography for photocrosslinking patterns within the same planes.^[30] However, to achieve the bioprinting of 3D structures with distinct materials between the layers, our current bioprinting system still requires polymerization of the bioinks at static flow conditions with the need of washing processes.

The advantage of our bioprinting platform in terms of fabrication speed would become more noticeable when fabrication time hampers cell viability in larger cell-laden constructs. The unique features of our bioprinter have significantly promoted the current level of control and printing speed among existing bioprinting techniques.^[29, 31] This concept is also expandable to as many bioinks as needed by simply increasing the number of inlet channels. In addition, the printing speed of our multi-material DMD bioprinting system may be further improved by carefully coordinating projection light and local oxygen levels to achieve continuous photocrosslinking of the bioinks in a layerless manner.^[32] The use of the proposed microfluidic chip, however, limited the physical size of the constructs that could be fabricated and the scale-up will demand alteration in the design of the chamber.

Experimental Section

DMD-based bioprinting platform:

Figure 1a shows the custom-built DMD-based bioprinting system used for the fabrication of multi-component constructs. A UV LED (M385LP1-C1; Thorlabs, Newton, NJ) mounted to a light collimator was used at a wavelength of 365 nm and a power of nearly 500 mW cm⁻². A Newport (Nashua, NH) power meter was used to determine the light intensity. Our digital models built with AutoCAD were converted to 2D bitmap slices and translated to spatially tilt a pattern of micromirrors on the DMD panel (DLP® LightCrafter™ 6500; Texas Instruments Inc., Dallas, TX). A stage controller was used to manage the three-axis stage movement, whereas the UV light source (Thorlabs) was directed via an optical path towards the DMD panel at a specific angle to facilitate light reflection through the projection optics to the stage. The thickness of the layers could be adjusted in 100-μm steps and the planar

resolution of the system was found to be around 10 μm (5×5 mm illumination area). This resolution was achieved utilizing a compound lens with 2-cm working distance (Figure 1b). Since the DMD reflects an array of square pixels and the layers are built on top of each other, the tolerance of the printing is important in the resolution of constructs [16]. Exposure times ranged from 1 to 20 s depending on the aperture of light and hydrogel composition. The DMD panel, the stage, and the UV light source were controlled by a microcontroller (Arduino UNO; Arduino, Italy). Figure 2b shows the printing sequence controlled by the Arduino program. While the pattern is being printed there is no liquid flowing in the chamber (stage 1 in Figure 3d); once the pattern is printed, the motor brings the chip up (stage 2 in Figure 3d); if the material is to be changed, the valve of the next material is turned on and the new material starts washing the one currently in the chamber (stage 3 in Figure 3d); an additional washing with buffer can be added if the material is hard to wash; finally, the motor brings the chip down to print the following layer. An open chamber shown in Figure 1c was also used to test single-material printing and characterize the optical setup.

Hydrogel preparations:

PEGDA ($M_n = 700$), 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO), and gelatin from porcine skin type A were purchased from Sigma-Aldrich (St. Louis, MO). TEMPO mitigates free radical migration distance leading to structure sharpness in high-aspect ratio constructs.^[17] High-purity distilled water was generated by Millipore system with a resistivity reading of 18.2 M Ω upon collection. Lithium phenyl-2,4,6-trimethyl-benzoyl-phosphinate (LAP) was purchased from BioBots (Philadelphia, PA). This photoinitiator has been extensively used for cellular studies.^[33] A 50% v/v PEGDA aqueous solution was prepared, and TEMPO (0.01% w/v) and LAP (1.0% w/v) were added to the solution. The mixture was heated to 80 $^{\circ}\text{C}$ for 1–3 h. The resulting PEGDA bioink was used to fabricate the structures presented in Figures S1. Food dyes and fluorescence beads were used to assist visualizations when necessary. For 3D constructs and cell study we used GelMA-7% w/v solution containing LAP (0.3% w/v), as shown in Figures S4. GelMA was also fabricated following the well-established protocol.^[34] In summary, we dissolved gelatin in PBS for 2 h at 60 $^{\circ}\text{C}$ under constant stirring to make a 10% w/v gelatin solution and then added 5% v/v methacrylic anhydride (Sigma-Aldrich), and subsequently stirred for 1 h at 60 $^{\circ}\text{C}$ and 500 rpm. Two volumes of pre-heated PBS were added and the solution was dialyzed for one week.

Multi-inlet microfluidic chip:

The microfluidic chip of the bioprinting platform (Figures 1a and 2a) was designed and fabricated. The chip model was designed using CorelDraw (Corel Corp, Ottawa, ON) software (see Supplementary Materials) and imported to a laser cutting machine (VLS 2.30 Desktop Laser, Universal Laser Systems Inc, Richmond, VA) for cutting PMMA sheets (1.6 mm in thickness; McMaster-Carr, Robbinsville, NJ). The mold included four 1-mm-wide inlets, connecting channels, one printing region of 10 mm in diameter, and one outlet. After merging the four inlets, the first semi-circular region was 4 mm wide and it connected to a short 2-mm-wide channel. We designed a smooth connection to the printing region with three curved branches so that the hydraulic resistance of each branch was approximately one-third the hydraulic resistance of one single channel. The four inlets were merged into a

wider region (4 mm in width) with a total length of 5 mm. PDMS precursor (Sylgard 184; Dow Corning, Midland, MI), prepared by an elastomer/curing agent ratio of 10:1, was poured onto the PMMA mold, cured at 85 °C for 2 h, and peeled off. A circular region assigned for printing was created using a customized punch (outer diameter: 10 mm) in the center of the PDMS chamber. Our design also included a thin PDMS membrane; we used spin coating (at 1000 rpm) of a PDMS drop on a glass slide, followed by curing at 85 °C for 2 h, to achieve this membrane. The patterned PDMS replica was manually bonded to the membrane and then sandwiched between two PMMA sheets, as depicted in Figure 2a. To connect the inlets and outlet, stainless steel adaptors (outer diameter: 0.5 mm) were used.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors gratefully acknowledge funding from the Office of Naval Research Young National Investigator Award, the National Institutes of Health (AR057837, DE021468, D005865, AR068258, AR066193, EB022403, EB021148, EB021857), and the Presidential Early Career Award for Scientists and Engineers (PECASE). Y.S.Z. acknowledges the National Cancer Institute of the National Institutes of Health Pathway to Independence Award (K99CA201603). A.K.M. acknowledges the Fonds de recherche du Québec – Santé (FRQS) postdoctoral fellowship and Canadian Institutes of Health Research (CIHR). D.N. acknowledges (I2C plan) Xunta de Galicia funding. H.G.H. also thanks Prof. Reza Bagheri (Sharif University of Technology, Tehran, Iran) for his support. The authors acknowledge Dr. Farideh Davoudi (Brigham and Women's Hospital, Harvard Medical School) for her contributions in performing cell assays and Mr. Xichi Wang (Brigham and Women's Hospital, Harvard Medical School) for his contributions in the animal study.

References

- [1]. Ozlem Y, Shih-Feng L, Binil S, Biofabrication 2009, 1, 045004. [PubMed: 20811113]
- [2]. Ma X, Qu X, Zhu W, Li Y-S, Yuan S, Zhang H, Liu J, Wang P, Lai CSE, Zanella F, Feng G-S, Sheikh F, Chien S, Chen S, Proct. Natl. Acad. Sci. U.S.A 2016, 113, 2206.
- [3]. Masters BR, Annual Review of Biomedical Engineering 2004, 6, 427.
- [4]. Sun W, Darling A, Starly B, Nam J, Biotechnology and Applied Biochemistry 2004, 39, 29. [PubMed: 14563211]
- [5]. O'Brien FJ, Harley BA, Yannas IV, Gibson L, Biomaterials 2004, 25, 1077. [PubMed: 14615173]
- [6]. Moroni L, de Wijn JR, van Blitterswijk CA, Biomaterials 2006, 27, 974. [PubMed: 16055183]
- [7]. Melchels FP, Feijen J, Grijpma DW, Biomaterials 2010, 31, 6121. [PubMed: 20478613]
- [8]. Michael S, Sorg H, Peck C-T, Koch L, Deiwick A, Chichkov B, Vogt PM, Reimers K, PLOS ONE 2013, 8, e57741. [PubMed: 23469227]
- [9]. Dean D, Wallace J, Siblani A, Wang MO, Kim K, Mikos AG, Fisher JP, Virtual and physical prototyping 2012, 7, 13. [PubMed: 23066427]
- [10]. Mitteramskogler G, Gmeiner R, Felzmann R, Gruber S, Hofstetter C, Stampfl J, Ebert J, Wachter W, Laubersheimer J, Additive Manufacturing 2014, 1, 110.
- [11]. Sun C, Fang N, Wu D, Zhang X, Sensors and Actuators A: Physical 2005, 121, 113.
- [12]. Stampfl J, Pettermann H, Liska R, in Biomimetics--Materials, Structures and Processes, Springer, 2011, 105.
- [13]. Raman R, Bhaduri B, Mir M, Shkumatov A, Lee MK, Popescu G, Kong H, Bashir R, Advanced healthcare materials 2015; Pan Y, Zhou C, Chen Y, Journal of Manufacturing Science and Engineering 2012, 134, 051011.
- [14]. Han L-H, Mapili G, Chen S, Roy K, Journal of Manufacturing Science and Engineering 2008, 130, 021005.

- [15]. Choi J-W, Kim H-C, Wicker R, Mater J. *Process. Technol* 2011, 211, 318.
- [16]. Chan V, Jeong JH, Bajaj P, Collens M, Saif T, Kong H, Bashir R, *Lab on a Chip* 2012, 12, 88. [PubMed: 22124724]
- [17]. Warner J, Soman P, Zhu W, Tom M, Chen S, *ACS Biomaterials Science & Engineering* 2016, 2, 1763.
- [18]. Zhang AP, Qu X, Soman P, Hribar KC, Lee JW, Chen S, He S, *Advanced Materials* 2012, 24, 4266. [PubMed: 22786787]
- [19]. Fung Y.-c., *Foundations of solid mechanics*, Prentice Hall, 1965.
- [20]. Nazari AM, Miri AK, Shinozaki DM, *Polymer Testing* 2016, 52, 85.
- [21]. Loessner D, Meinert C, Kaemmerer E, Martine LC, Yue K, Levett PA, Klein TJ, Melchels FPW, Khademhosseini A, Hutmacher DW, *Nat. Protocols* 2016, 11, 727. [PubMed: 26985572]
- [22]. Wang L, Jacques SL, Zheng L, *Comput. Methods Programs Biomed* 1995, 47, 131. [PubMed: 7587160]
- [23]. Carmeliet P, Jain RK, *Nature* 2000, 407, 249; Bhatia SN, Ingber DE, *Nature* 2014, 201, 4. [PubMed: 11001068]
- [24]. Nieto D, Couceiro R, Aymerich M, Lopez-Lopez R, Abal M, Flores-Arias MT, *Colloids and Surfaces B: Biointerfaces* 2015, 134, 363. [PubMed: 26218523]
- [25]. Zhang YS, Duchamp M, Oklu R, Ellisen LW, Langer R, Khademhosseini A, *ACS Biomaterials Science & Engineering* 2016, 2, 1710. [PubMed: 28251176]
- [26]. Oh HH, Lu H, Kawazoe N, Chen G, *Journal of Biomaterials Science, Polymer Edition* 2012, 23, 2185. [PubMed: 22127352]
- [27]. Schumacher JJ, Dings RP, Cosin J, Subramanian IV, Auersperg N, Ramakrishnan S, *Cancer research* 2007, 67, 3683. [PubMed: 17440080]
- [28]. Hetrick EM, Prichard HL, Klitzman B, Schoenfisch MH, *Biomaterials* 2007, 28, 4571. [PubMed: 17681598]
- [29]. Wicker RB, MacDonald EW, *Virtual and Physical Prototyping* 2012, 7, 181.
- [30]. Dendukuri D, Pregibon DC, Collins J, Hatton TA, Doyle PS, *Nat. Mater* 2006, 5, 365 [PubMed: 16604080] Panda P, Ali S, Lo E, Chung BG, Hatton TA, Khademhosseini A, Doyle PS, *Lab Chip* 2008, 8, 1056. [PubMed: 18584079]
- [31]. Liu W, Zhang YS, Heinrich MA, De Ferrari F, Jang HL, Bakht SM, Alvarez MM, Yang J, Li Y-C, Trujillo-de Santiago G, Miri AK, Zhu K, Khoshakhlagh P, Prakash G, Cheng H, Guan X, Zhong Z, Ju J, Zhu GH, Jin X, Shin SR, Dokmeci MR, Khademhosseini A, *Advanced Materials* 2016, n/a.
- [32]. Tumbleston JR, Shirvanyants D, Ermoshkin N, Janusziewicz R, Johnson AR, Kelly D, Chen K, Pinschmidt R, Rolland JP, Ermoshkin A, Samulski ET, DeSimone JM, *Science* 2015, 347, 1349. [PubMed: 25780246]
- [33]. Zhang YS, Davoudi F, Walch P, Manbachi A, Luo X, Dell'Erba V, Miri AK, Albadawi H, Arneri A, Li X, Wang X, Dokmeci MR, Khademhosseini A, Oklu R, *Lab on a Chip* 2016, 16, 4097. [PubMed: 27722710]
- [34]. Nichol JW, Koshy S, Bae H, Hwang CM, Yamanlar S, Khademhosseini A, *Biomaterials* 2010, 31, 5536. [PubMed: 20417964]

Figure 1.

a) Planar schematics showing the setup of the bioprinter, including a UV lamp (385 nm), optical lenses and objectives, a DMD chip, and a microfluidic device. **b)** Schematic showing the actual setup of the entire optical platform. **c)** Schematic showing an open-chamber microfluidic chamber used to create single-material printouts.

Figure 2.

a) Schematic showing the assembly of the microfluidic chip having four inlets and one common outlet. **b)** The operation of the microfluidic device for consecutive injection of different bioinks and the washes in between the injections. **c)** The defined CFD model and the velocity profile (m/s) of PEGDA (with a density 1.06 kg/m^3 and a viscosity $1 \times 10^{-5} \text{ Pa s}$) in the closed chamber under sinusoidal fluid flow. **d-f)** The role of mixing and washing observed by flow streamlines in GelMA solution (15% w/v) mixed by food dye in the microfluidic chip for a star pattern, two rectangular patterns (made of PMMA molds), and no pattern, respectively.

Figure 3.

a) Schematic showing the microfluidic chip containing a moving part at the center of the bottom chamber. **b)** Computational domain of the finite element analysis built for an isotropic, incompressible, hyperelastic membrane supported on the rigid piston. **c)** Simulation result showing principle strain and stress values of the PDMS membrane at 4-mm displacement. **d)** Schematics showing the four-step bioprinting process inside the microfluidic chip for fabricating 3D objects. **e-g)** Examples of multi-component bioprinted constructs: **e)** a two-component GelMA-7% construct filled by fluorescent dyes (left) and a three-component pattern of colored PEGDA-50% (right); **f)** a 3D fluidic mixer made by three different colors (white, orange, blue) printed from PEGDA-50%; and **g)** a single-component (green) and a three-component (white, blue, purple) star-shaped pyramid of PEGDA-50%.

Figure 4.

a) A tumor angiogenesis model: *i)* schematic showing the tumor angiogenesis; *ii)* schematic of the mask for printing; *iii)* bioprinted microvasculature in PEGDA; *iv)* bioprinted MCF7 cell (red)-laden microvascular bed of GelMA further seeded with HUVECs (green) in the channels. **b)** A skeletal muscle model: *i)* schematic showing the skeletal muscle tissue; *ii)* schematic of the mask for printing; *iii)* bioprinted structure of GelMA containing patterned C2C12 cells (red) and fibroblasts (blue) after 48 h of culture; *iv)* Presto blue measurements of cell proliferation in the bioprinted structures. **c)** A tendon-to-bone insertion model: *i)* schematic of the tendon-to-bone insertion site; *ii)* schematic of the mask for printing; *iii)* bright-field optical micrograph showing a bioprinted dye-laden GelMA structure; *iv)* bioprinted structure of GelMA containing patterned osteoblasts (blue), MSCs (red), and fibroblasts (green).

Figure 5.

a) A concentration-gradient model generated by multi-material DMD bioprinting: *i)* schematic of the construct showing the PEGDA (35% v/v) frame and three GelMA strips of 5, 10, and 15% w/v mass concentrations with a uniform thickness of 1 mm; *ii)* a bioprinted model where the GelMA strips contained green fluorescent beads; *iii)* the rat subcutaneous model used to assess the bioprinted constructs. **b)** Photographs showing the retrieved implants at Day 10 and Day 30, along with confocal images of the retrieved constructs at Day 30 stained for nuclei (blue) and for CD31 (red), where the bright-field views were pseudo-colored in green. **c)** Immunostaining of the retrieved implants for CD31 (red), for different GelMA concentrations (5, 10, and 15%), in the absence and presence of VEGF; the nuclei were counterstained with DAPI (blue). **d)** H&E staining of the retrieved implants for different GelMA concentrations, in the absence and presence of VEGF.